Back to mobile site
Get it on Google Play

FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer

June 12, 2026 4:10 PM EDT Send to a Friend
The U.S. Food and Drug Administration approved Merck's (NYSE: MRK) KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login